Global Brain has invested in Veritas In Silico Inc. (VIS), a biotech company focusing on small molecule drug discovery targeting mRNA, through its KDDI Open Innovation Fund III (KOIF III) and GB-VII Growth Fund Investment Limited Partnership (GB-VII).
VIS has developed their ibVIS platform that combines informatics and experimental biology to discover small molecule drugs (SMDs) targeting motifs on the mRNA. The ibVIS platform can be applied to discovery of not only SMDs but also antisense oligonucleotides (ASOs). VIS can meet a wide range of drug discovery needs for pharmaceutical companies by using ASOs for rare diseases and SMDs for chronic diseases and infectious diseases. VIS’s mission is to build a society where every patient, especially those with diseases that currently have no satisfactory treatment, can look forward to a brighter future through the realization of mRNA-targeted drugs.
Global Brain decided to invest in VIS, thinking highly of their unique platform technology and strong management team. Through this investment, Global Brain will proactively leverage its resources to support VIS’s further growth both in Japan and overseas.
About VIS
- Location
- Shinagawa-ku, Tokyo, Japan
- Representative
- Shingo Nakamura
- Founded
- November 2016
About KOIF III
- Name
- KDDI Open Innovation Fund III
- General Partner
- Global Brain Corporation
- Fund Size
- 20 Billion JPY
About GB-VII
- Name
- GB-VII Growth Fund Investment Limited Partnership
- General Partner
- Global Brain Corporation
About Global Brain
- Location
- Tokyo, Japan
- Representative
- Yasuhiko Yurimoto
- Founded
- January 1998